Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity

Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity

IntroductionTNFα inhibitor (TNFi) immunogenicity in rheumatoid arthritis (RA) is a major obstacle to its therapeutic effectiveness. Although methotrexate (MTX) can mitigate TNFi immunogenicity, its adverse effects necessitate alternative strategies. Targeting nuclear factor of activated T cells (NFA...

Full description

Saved in:
Bibliographic Details
Main Authors: Aboli Bhingarkar, Yuyin Wang, Keito Hoshitsuki, Katherine Marie Eichinger, Sanjay Rathod, Yin Zhu, He Lyu, Andrew T. McNutt, Larry W. Moreland, Lee McDermott, David R. Koes, Christian A. Fernandez
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
rheumatoid arthritis
antidrug antibodies (ADA)
NFAT (nuclear factor of activated T cells)
methotrexate
adalimumab
duvelisib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1397995/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1397995/full

Similar Items